As a type of CTA, recent studies have also found SPA17 expression in various tumors, including ovarian cancer, breast cancer, multiple myeloma, cervical cancer, endometrial cancer, and non-small cell lung cancer (11–13). Here, SPA17 is linked to ovarian carcinoma.